Disparities in tissue-based biomarker testing among US Medicare beneficiaries with prostate cancer
This study reveals high geographic variability in tissue-based biomarker testing for prostate cancer. Further, Black and Hispanic patients were less likely to receive testing. Our findings highlight regional practice variation in the use of advanced, not routinely recommended tests and underscore the need to minimize disparities in diagnostic access.
Authors
- Caroline M. Moore (ORCID: https://orcid.org/0000-0003-0202-7912)
- Zhiyu Qian
- Stephan Korn
- Jianyi Zhang (ORCID: https://orcid.org/0000-0002-3955-6554)
- Stacy Loeb (ORCID: https://orcid.org/0000-0003-3933-9207)
- Klara K. Pohl
- Kerry L. Kilbridge (ORCID: https://orcid.org/0000-0001-7460-6273)
- Hanna Zurl
- Adam S. Kibel (ORCID: https://orcid.org/0000-0002-9446-7781)
- Stuart R. Lipsitz (ORCID: https://orcid.org/0000-0003-2619-1389)
- Alexander P. Cole (ORCID: https://orcid.org/0000-0002-0049-8529)
- Huma Q. Rana (ORCID: https://orcid.org/0000-0002-1598-6752)
- Andrea Piccolini (ORCID: https://orcid.org/0009-0004-6601-1244)
- Shahrokh F Shariat
- Quoc-Dien Trinh (ORCID: https://orcid.org/0009-0002-6752-0388)
Institutions
- Al-Ahliyya Amman University (JO)
- Brigham and Women's Hospital (US)
- Humanitas University (IT)
- Harvard University (US)
- University of Pittsburgh (US)
- Medical University of Graz (AT)
- Cornell University (US)
- Charles University (CZ)
- NYU Langone Health (US)
- Dana-Farber Cancer Institute (US)
- Cancer Genetics (United States) (US)
- Karl Landsteiner Society (AT)
- IRCCS Humanitas Research Hospital (IT)
- University College London (GB)
- New York University (US)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1093/jncics/pkaf051
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Intuitive Surgical
- Les Laboratories Pierre Fabre
- Max Kade Foundation
- Astellas Pharma
- Ipsen
- Centers for Disease Control and Prevention
- National Cancer Institute